An interventional study of pegylated liposomal Doxorubicin (CAELYX) & Carboplatin and Paclitaxel & Carboplatin in Epithelial Ovarian Cancer, sponsored by King Faisal Specialist Hospital & Research Center. Completed. Per ClinicalTrials.gov, last updated 2015-12-17.
Sponsored by King Faisal Specialist Hospital & Research Center · Not applicable, Interventional, and Treatment
Multi-national, randomized, phase III, GCIG Intergroup study comparing pegylated liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in patients with epithelial ovarian cancer in late relapse. (CALYPSO)
2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.
This study's enrollment of 8 is below the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →King Faisal Specialist Hospital & Research Center is the lead sponsor of 98 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Chemotherapy
Chemotherapy
overall survival
Time frame: overall
No study locations are listed for this record.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
King Faisal Specialist Hospital & Research Center